10-Q quarterly report · filed Nov 4, 2026

Edwards Lifesciences (EW) Q3 2026 10-Q Quarterly Report

Short answer

Edwards Lifesciences (EW) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.7B (up 10.5% year over year) with net income of $308M.

Q3 2026 key financials · XBRL

Revenue
$1.7B
+10.5% YoY · −1.5% QoQ
Net income
$308M
+5.6% YoY · +27.1% QoQ
Operating margin
17.4%
Gross margin
78.5%
EPS (diluted)
$0.54
+10.2% YoY · +31.7% QoQ

Source: XBRL data from the Edwards Lifesciences (EW) Q3 2026 10-Q on SEC EDGAR. USD.

Edwards Lifesciences Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $1,715.5M, up 10.5% YoY from $1,553.1M
  • TMTT best-performing segment: $209.5M, up 44.3% YoY; Surgical lowest growth at 2.5%
  • Effective tax rate 17.0% vs 16.1% YoY; impairment charges $220.2M
  • Operating cash flow $1,266.0M, up $121.7M; share repurchases $714.0M
  • Tariffs pose potential demand and cost headwinds; 2026 Pillar Two tax expense expected at approximately $45.0M

Risk Factors

  • No material changes to risk factors reported since the December 31, 2025 Form 10-K
  • Carried-forward risks remain governed by the 2025 Annual Report’s Risk Factors section

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Edwards Lifesciences quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.